research use only
Cat.No.S8978
|
In vitro |
DMSO
: 50 mg/mL
(73.65 mM)
Water : 10 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 678.81 | Formula | C38H47O7PS |
Storage (From the date of receipt) | 2 years -20°C liquid |
|---|---|---|---|---|---|
| CAS No. | 845959-50-4 | -- | |||
| Synonyms | MitoQ10 mesylate, Mitoubiquinone mesylate | SMILES | CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)[O-] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
mitochondria
ROS
|
|---|---|
| In vitro |
Mitoquinone blocks H2O2-induced intracellular ROS responses inmurine pancreatic acinar cells. Mitoquinone does not reduce mitochondrial depolarisation induced by either cholecystokinin (CCK) or bile acid TLCS. Mitoquinone increases basal and CCK-induced cell death in a plate-reader assay. |
| In vivo |
In a TLCS-induced AP model Mitoquinone treatment is not protective. In AP induced by caerulein hyperstimulation (CER-AP), Mitoquinone exerts mixed effects. Thus, partial amelioration of histopathology scores is observed but without reduction of the biochemical markers pancreatic trypsin or serumamylase. Lungmyeloperoxidase and interleukin-6 are concurrently increased by Mitoquinone in CER-AP. Mitoquinone causes biphasic effects on ROS production in isolated polymorphonuclear leukocytes, inhibiting an acute increase but elevating later levels. |
References |
(data from https://clinicaltrials.gov, updated on 2025-11-14)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07228208 | NOT_YET_RECRUITING | Type 2 Diabetes (T2DM); Endothelial Dysfunction |
Medical College of Wisconsin |
2026-09-01 | |
| NCT03586414 | ACTIVE_NOT_RECRUITING | Diastolic Dysfunction |
University of Colorado, Denver |
2021-08-01 | |
| NCT06424756 | RECRUITING | Healthy |
University of Georgia |
2024-07-01 | PHASE2 |
| NCT07406243 | NOT_YET_RECRUITING | Aging; Postmenopause |
Colorado State University |
2026-04 | |
| NCT05373043 | RECRUITING | Long-COVID |
VA Office of Research and Development |
2022-11-01 | |
| NCT07229261 | RECRUITING | Preeclampsia; Pregnancy |
Medical College of Wisconsin |
2026-03-18 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.